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One of the oldest paradoxes in  immunology is that  the  kind of immunological response 
obtained depends critically upon the route of administration of antigen. Nowhere is this better 
illustrated than  in the case of contact sensitivity to DNFB 1 (1-fluoro-2,4-dinitrobenzene). In 
mice, DNFB applied topically to the skin produces contact sensitivity. The same compound 
injected intravenously produces profound specific immunologic unresponsiveness (tolerance) to 
DNFB (1). The understanding and resolution of this paradox requires detailed knowledge of 
the different methods by which the host processes the topical or i.v. antigens. A large body of 
data indicates that  the real immunogen  (for topical DNFB)  and  the real tolerogen (for i.v. 
DNFB) are reaction products produced by covalent coupling of DNFB to self components (2). 
We do not know yet what these products are, but we have extensively studied the tolerance to 
DNFB induced by treating animals with DNFB coupled to syngeneic lymphoid cell membranes 
(DNP-LC) (3, 4). This unresponsiveness has been shown to be an extremely efficient, exquisitely 
specific form of tolerance. In addition, we have separated the mechanisms of tolerance in this 
system into two distinct pathways (5).  Mice injected with DNP-LC may appear tolerant by 
virtue of one or the other (or both) of two antigen-specific mechanisms: (a) a rapidly induced, 
long-lasting period of clone inhibition, and  (b)  a  transient  period of suppressor T-cell  (T,) 
activity. In addition to the profound tolerogenic activity of hapten-modified lymphoid cells on 
T-cell-mediated responses,  this  form  of tolerogen  has  also  been  shown  to  be  effective for 
induction of unresponsiveness in B-cell responses (6, 7). 
In thinking about the role of membrane-bound DNP in inducing tolerance, we wanted to 
know whether these concepts could be generalized to apply to protein antigens. To study this 
in mice, one needs convenient methods to induce cell-mediated immunity (CMI) to proteins 
and to test the immunogenicity and tolerogenicity of membrane-bound proteins. 
Recently, improved methods of inducing and eliciting CMI to proteins in mice have been 
developed, using complete Freund's adjuvant (CFA) for induction (8) and measurement of ear 
swelling for  elieitation  (9).  Other  work  has  shown  that  contact  hypersensitivity to  simple 
chemicals can be induced by injection of hapten-coupled autologous cells (10,  11). More recent 
experiments indicate that vastly different responses can be elicited with hapten-modified cells 
depending  on  the  route  of injection  (12,  13). i.v.  injection  of spleen  cells  modified  with 
trinitrophenyl (TNP) or azobenzenearsonate lead to the induction of both tolerance and Ts, 
whereas s.c. injection of hapten-modified cells lead to the induction of a delayed-type contact 
sensitivity response. 
* Supported in part by U. S. Public Health Service, National Institutes of Health grant AI-12685. 
:~ Recipient of U. S. Public Health Service Young Investigator Award AI-14913. 
t Abbreviations used in this paper: ABA, azobenzenearsonate;  BSS, balanced salt solution; C', guinea pig 
complement; CFA, complete Freund's adjuvant; CMI, cell-mediated immunity; Cyt C, horse cytochrome 
C; DNFB, l-fluoro-2,4-dinitrobenzene; DTH, delayed type hypersensitivity; ECDI,  1-ethyl-3-(3-dimethyl- 
aminopropyl) carbodimide HCI;  HoGG, horse gamma globulin;  HoGG-LC,  HoGG-modified  lymphoid 
cells; MHC,  major histocompatibility complex;  NRS,  normal rabbit serum;  OVA, ovalbumin;  Tom 
delayed hypersensitivity T cells; "Is, suppressor T cells; TNP, trinitrophenyl. 
758  J. Exp. MED. © The Rockefeller University Press • 0022-1007/79/03/0758/16/$1,00 
Volume 149  March 1979  758-773 S.  D.  MILLER, R.  P  WETZIG, AND H.  N.  CLAMAN  759 
Therefore, we followed the earlier experiments of Battisto and Bloom (14,  15) who showed 
that bovine gamma globulin coupled to isologous guinea pig spleen cells could induce tolerance 
to both humoral antibody production and delayed hypersensitivity responses, and combined 
those concepts with the recent developments concerning CMI in the mouse. 
The present study was designed (a) to produce a reliable method for inducing CMI to protein 
antigens in a  mouse model without using CFA, and  (b) to examine the immunogenicity and 
tolerogenicity of membrane-bound  proteins in  this  model.  Furthermore,  we  compared  the 
tolerogenicity of free  and  membrane-bound  protein,  and  explored  the  dual  mechanisms 
involved in this tolerance. 
Materials  and  Methods 
Animals.  Female BALB/c mice were obtained from  Cumberland  Farms, Clinton, Tenn. 
Male CBA and SJL mice were obtained from The Jackson Laboratory, Bar Harbor, Maine. 
Mice were age-matched for each experiment and received pelleted food and water ad lib. 
Antigens and Chemicals.  Cohn Fraction II of horse gamma globulin (HoGG) (lot 82-254) and 
crystallized ovalbumin (OVA) (lot 95-051-2) were both obtained from Miles Laboratories Inc., 
Miles Research Products, Elkhart, Ind. Cytochrome C  (Cyt C) from horse heart (type III--Lot 
1BC-7540)  was obtained from Sigma Chemical Co., St. Louis, Mo.  1-Ethyl-3-(3-dimethylami- 
nopropyl) carbodimide HCi  (ECDI)  was  obtained  from  Story Chemical Corp.,  Muskegon, 
Mich. 
Preparation of  Antigen-Modified Lymphoid Cells.  Spleen cell suspensions were prepared in Hanks' 
balanced salt solution (HBSS) as described previously (4). Erythrocytes were lysed by treatment 
with isotonic Tris-buffered ammonium chloride, the cells washed two times with HBSS, and 
once with 0.9% NaC1. 400 ×  108 cells were pelleted in a  17  ×  100 mm Falcon plastic tube and 
re.suspended in 1.5 ml of antigen diluted in 0.9% NaCI (40 mg/ml for HoGG and 20 mg/ml for 
Cyt C). To the above, 0.25 ml of freshly prepared ECDI (100 mg/ml in saline) was added. The 
reaction was allowed to proceed for  1 h  at 4°C, after which the antigen-modified cells were 
washed three times with HBSS, and adjusted to a concentration of 10"/ml. To determine the 
amount  of HoGG coupled, l~I-labeled HoGG was added to the reaction mixture in tracer 
amounts. A  series of five separate experiments showed that an average of 5.33  :tz  0.45 #g of 
HoGG was coupled per 107 lymphoid cells. 
Deaggregation of HoGG.  30 mg/ml HoGG was deaggregated by centrifugation at 40,000 rpm 
for  150  rain in a  swinging bucket  SW 50.1  rotor (16).  The  upper third of the solution was 
removed and diluted to a concentration of 50 #g/ml. 
Sensitization and Elicitation of CMI.  Sensitization to various proteins was accomplished by 
two  methods.  First, antigens in  the optimal concentrations were emulsified in  CFA  (Difco 
Laboratories, Detroit, Mich.). Mice were injected s.c. at the base of the tail with a total emulsion 
vol of 50 #1  (17).  Optimal  sensitization amounts  for the  various antigens were  as  follows: 
HoGG--250 #g; OVA--100 #g; and Cyt C--100 #g. In the second method, antigen-modified 
cells were injected s.c. (12). Mice were injected in four positions beneath the dorsal skin with a 
total of 3-5  ×  l0  T HoGG-LC in a  total vol of 0.2 ml. For elicitation of CMI, mice were ear 
challenged with the appropriate antigen 7 d after antigen-CFA or 6 d  after antigen-modified 
lymphoid cells (LC). Ear thickness was quantitated using a  Mitutoya engineer's micrometer 
(Sehlesinger's Tools, Brooklyn, N. Y.); the dorsal surface of the ear was then injected s.c. with 
10  #g  of antigen  contained  in  10  #1  of saline using  a  27  gauge  needle.  24  h  postantigen 
challenge, the degree of ear thickness was again measured and results expressed in units of 10  -~ 
inches. 
Induction and Transfer of Sensitivity.  For transfer of sensitivity, mice were sensitized by s.c. 
injection of 60  ×  106 HoGG-LC divided into four sites on the dorsal skin and the two front 
footpads. 4 d  postsensitization, draining lymph nodes (inguinal, axillary, and brachial) were 
collected and  10  s viable ceils transferred to normal, syngeneic recipients. Recipient mice were 
ear challenged within  1 h of cell transfer and the degree of ear swelling measured 24 h  later. 
Induction and Transfer of Tolerance.  Mice were injected i.v. with  108 HoGG-LC or l0  s Cyt C- 
LC at  varying times before sensitization or transfer of tolerance.  For transfer of tolerance, 
peripheral and mesenterie lymph nodes and/or spleens were collected and single cell suspensions 
prepared  in  Mishell-Dutton  balanced  salt  solution  (BSS).  From  108  to  1.6  ×  108  donor 760  IMMUNITY AND TOLERANCE WITH ANTIGEN-MODIFIED LYMPHOCYTES 
lymphocytes were injected i.v. into normal recipients. Control mice received either no cells or 
an equivalent  number of cells  from normal donors. The recipient  and  control groups were 
sensitized  within  1 h after transfer and challenged 6-7 d later. The degree of donor tolerance 
or tolerance transferred to normal recipients was expressed as percent tolerance according to 
the following formula using ear swelling values: 
percent tolerance =  1-[experimental -  negative control/positive control -  negative control] 
x  100%. 
Anti-O Serum Treatment.  Rabbit anti-brain-associated 0 serum was prepared and absorbed 
according to the method of Golub  (18).  Lymphoid cells were reacted with  1.0 ml of a  1:10 
dilution of normal rabbit serum (NRS) or anti-0 serum/10  s cells for 45 min at 4°C, washed 
once in  BSS,  and  then  incubated with  1.0 ml of a  1:6 dilution  of guinea pig complement 
(containing 10 #g/ml DNAse)/10  s cells for 30 min at 37°C. The cells were then washed twice 
in BSS and recounted for cell transfer. 
In  Vitro Culture.  After determination  of in vivo ear swelling,  draining lymph nodes were 
used as a source of cells for antigen-induced proliferation. For mice sensitized in the base of the 
tail, these consisted of inguinal and periaortic nodes. For mice sensitized s.c. with HoGG-LC, 
these consisted of inguinal, axillary, and brachial nodes. Cell suspensions were prepared and 
washed  in  BSS and  the  cells  were  cultured  in  tissue  culture  medium  prepared  exactly as 
described  by Corradin  et  al.  (17).  Briefly,  this  consisted  of modified  Click's  (19) medium 
containing 10% fetal calf serum and 2-mercaptoethanol. Cell suspensions were dis~e,  nsed into 
Costar flat-bottom microwell plates, each well receiving 0.2-ml vol containing 4 ×  10  lymphoid 
cells. Antigens (100 #g/well of HoGG, OVA, or Cyt C) were added in a  10 #1 vol. The plates 
were incubated at 37°C in a humidified atmosphere of 5% CO2, 95% air for 120 h. Cultures 
were pulsed for the final 24 h of culture with  1 #Ci (in  10 #1) of [3H]thymidine (6 Ci/m tool, 
Schwarz/Mann Div., Becton, Dickinson & Co., Orangeburg, N. Y.). Cultures were harvested 
with  an automated sample  harvester,  and  radioactive  measurements  of trichloroacetic acid 
insoluble material determined in a Packard liquid scintillation counter. 
Statistical Analyses.  The statistical significance of  differences in ear swelling reactions between 
experimental groups was calculated with the Student's t test. 
Results 
Induction of Sensitization with Antigen-CFA or Antigen-Modified  Lymphoid Cells.  In early 
attempts  to  produce  a  reliable  method  of inducing  CMI  to  protein  antigens,  we 
compared two regimens:  the sensitization  of BALB/c mice with  HoGG-CFA in the 
base  of the  tail  vs.  the  s.c.  injection  of HoGG-LC  into  the  back.  Table  I  shows  a 
comparison of these two methods in terms of both ear swelling in vivo and antigen- 
induced T-cell proliferation in vitro. Both methods resulted in readily detectable ear 
swelling and  in  vitro  proliferative  responses.  Peak  responsiveness  with  HoGG-CFA 
occurred  with  250 #g of antigen  (exp.  1--group C).  Peak  responsiveness  upon  s.c. 
sensitization with HoGG-LC occurred with 3-5  X  107 modified cells (exp. 2--groups 
B  and C). The degree of in vivo ear swelling correlated closely with the extent  of in 
vitro proliferation. 
The kinetics  of the ear swelling reaction  postehallenge  had  typical  delayed char- 
acteristics  (data not shown). There was very little response at 4 h. Extensive swelling 
was present at 24 h; it declined dramatically after that, but was still significant at 48 
h. 
To determine the phenotype of the cell responsible for the observed reactivity,  l0  s 
viable lymph node cells from sensitized  mice were treated  in vitro with either NRS 
+  C' or anti-0  +  C' and transferred  to normal, syngeneic recipients.  A  third  group 
received  0.4  ml  of serum  from  sensitized  animals.  The  results  shown  in  Fig.  1 
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TABLE  I 
Comparison of the Induction of Sensitivity to HoGG by Intratail Injection of HoGG-CFA vs. Subcutaneous 
Injection of HoGG-Modified LC 
Exp.  Exp.  Sensitization regimen  Route*  Ear swelling:]:  In vitro re- 
no.  group  sponse§ 
X 10  -4 inch "4" SEM  A cpm 
A  50 #g HoGG-CFA  i.t.  22.5 ±  1.3  19,070 
B  100 ~g HoGG-CFA  i.t.  23.9 ±  3.5  16,600 
C  250/xg HoGG-CFA  i.t.  38.5 ±  4.9  26,580 
D  500 #g HoGG-CFA  i.t.  20.6 :t= 2.0  29,030 
E  Saline-CFA  i.t.  1.9 ±  2.2  -1,800 
A  107 HoGG-LC  s.c.  30.1  ±  2.4  16,830 
B  3 X  107 HoGG-LC  s.c.  46.3 :l: 3.4  28,570 
C  5 X  107  HoGG-LC  s.c.  51.7 ±  3.1  29,190 
D  5 X  10  7 Sham-LC  s.c.  5.5 ±  1.1  -1,800 
* Route of sensitization: i.t. -- intratail; s.c. =, subcutaneously in the back. 
Mean ear swelling  response of groups of four to five mice ±  SEM. 
§ Mean A cpm in vitro response 0~ cpm  100 #g/culture  HoGG -  )~ cpm Nil) for quadruplicate  5-d 
cultures. 
Cells or Serum  Antiserum 
Transferred  Treatment 
I0 8  Sensi- 
tized LNC  NRS  + C' 
10 8  Sensi- 
tized LNC  Anfi-g  ÷ C' 
0,S  ml 
Serum 
None 
Ear  Swelling(x|0 "4  inch )  -+  $EM 
5  10  15  20  25 
i  I  |  I  I 





Fro.  1.  Transfer of sensitivity induced by subcutaneous injection of HoGG-modified lymphoid 
cells is mediated by 0-sensitive  T cells, not by immune serum. Donor mice were sensitized by s.c. 
injection with a total of 6 X 107 HoGG-LC 4 d before transfer of draining  LN cells. Values represent 
mean 24 h ear swelling ±  SEM for groups of five mice. NS, not significantly different than negative 
control (group D). 
sensitized LN cells (group A). However, treatment of the cells with anti-0 +  C' before 
transfer abrogated  this reaction. Recipients receiving serum from sensitized donors 
also  showed  no  significant ear  swelling. Together,  the  data  from  the  kinetic and 
transfer experiments indicate that the response is delayed-in-time  and requires T  cells. 
Comparison of  the Tolerogenic Nature of  Equivalent Amounts of  Free and Cell-Bound Antigen.  In 
recent years, our laboratory has been extensively studying the concept that T  cells are 
best tolerized by membrane-associated antigens. In this case, we used the model of 
contact sensitivity to DNFB and studied the induction of tolerance with DNP-LC (4, 
5).  We  asked  if protein tolerogens showed  the  same phenomenon. To  do  this,  we 
compared the tolerogenicity of free HoGG compared with HoGG coupled to lymphoid 
cells with and without carbodimide. A series of experiments using l~SI-labeled HoGG 
revealed that  5.3  ±  0.45 #g of HoGG was  coupled per  107  lymphoid cells by the 
earbodimide procedure and 1.28  ±  0.22 #g/10  T  cells without carbodimide. Therefore, 762  IMMUNITY AND TOLERANCE WITH ANTIGEN-MODIFIED LYMPHOCYTES 
TABLE II 
Comparison of the Tolerogenic Capacity of Soluble vs.  Cell-Bound  HoGG in BALB/c Mice 
In vivo response~ 
Exp.  Exp.  Day -7 i.v.  Day 0  In vitro 
no.  group  tolerogen*  sensitization~  Ear  Toler-  response[[ 
swelling  ante 
X 10  -4 inch 
%  A cpm  +  SEM 
A  10  s  HoGG-LC  (50  #g  250 #g HoGG-CFA  12.9 =l= 0.9  84.5¶  1,130¶ 
bound) (+ ECDI) 
B  10  a  HoGG-LC  (13  #g  250 #g HoGG-CFA  29.5 =l= 3.2  45.7¶  23,950¶ 
bound) (- ECDI) 
C  50  #g  Deaggregated  250 #g HoGG-CFA  49.4 :t: 2.6  -0.7  48,240 
HoGG 
D  50 #g Native HoGG  250 lag HoGG-CFA  44.4 3= 2.5  11.0  38,490 
E  0.5 mg Native HoGG  250 #g HoGG-CFA  45.2 :t:  1.3  8.9  42,290 
F  5.0 mg Native HoGG  250 #g HoGG-CFA  43.9 +  2.6  11.9  45,810 
G  --  250 p.g HoGG-CFA  49.1  :l: 2.7  --  43,210 
H  --  Saline-CFA  6.3 +  2.2  --  -5,890 
A  l0  s  HoGG-LC  (50  #g  3  ×  l0  T HoGG-LC  7.9 +  1.3  87.5¶  -1,200¶ 
bound)  s.c. 
B  --  3  ×  l0  T  HoGG-LC  37.4 :l:  1.5  --  14,720 
S.C. 
C  --  --  3.7 ::l: 0.8  --  -930 
* Mice were tolerized by i.v. injection of the indicated materials 7 d before sensitization. 
~: Mice in exp. 1 were sensitized with 250 #g HoGG-CFA i.t.; mice in exp. 2 were sensitized 3 ×  107 HoGG- 
LC s.c. 
§ Mean ear swelling response for groups of four mice +  SEM at 7 d (exp. 1) or 6 d (exp. 2) postsensitization. 
II Mean A cpm in vitro responses (X cpm 100 #g/culture HoGG -  X cpm Nil) for quadruplicate 5-d cultures. 
¶ Significantly  less than positive controls P <  0.001. 
BALB/c mice were injected i.v. with either  l0  s HoGG-LC  or the equivalent amount 
of native  HoGG  or  deaggregated  HoGG  on  day-7  (Table  II).  Additional  groups 
received  10  ×  (0.5 mg)  or  100  ×  (5.0 mg) of native HoGG. On day 0, experimental 
and  positive control  mice  in exp.  1  received  250  ~g  HoGG-CFA  i.t.  and  in exp.  2 
received  3  ×  107  HoGG-LC  s.c.  Negative  controls  received  saline-CFA or  sham- 
modified  cells,  respectively.  All  groups  were  ear  challenged  with  10  #g,  and  ear 
swelling and in vitro proliferation determined 24 h  later. The results shown in Table 
II indicate that prior injection of soluble HoGG  (either native or deaggregated)  up to 
a  dose of 5.0 mg had no effect on the CMI  response to HoGG-CFA  as measured via 
ear  swelling  or  in  vitro  proliferation.  However,  i.v.  injection  of  l0  s  HoGG-LC 
profoundly suppressed the development of both the in vivo and in vitro manifestations 
of the  CMI  response  induced  by  antigen-CFA  (exp.  1--group  A)  or  by  antigen- 
modified lymphoid cells given s.c.  (exp.  2--group  A). i.v. injection of LC, which had 
been  incubated with  HoGG  but without  ECDI,  led  to  intermediate  levels of unre- 
sponsiveness measured  both  in  vivo and  in vitro  (exp.  1--group  B).  The  degree  of 
tolerance  is  approximately  what  would  be  expected  with  1/4  the  dose  of  ECDI- 
coupled HoGG  (see Fig.  2  and later discussion of dose-response).  Suppression of the 
CMI response to HoGG  by prior i.v. injection of HoGG-LC  was not restricted to the 
BALB/c strain, as CBA mice were also tolerized by this treatment  (data not shown). S.  D.  MILLER,  R.  P  WETZIG,  AND  H.  N.  CLAMAN 
Ear Swelllng(xl0 "4 inch)  z  SEM  ° 
Day of  Dose  of  0  10  20  30 
Group  Tolerization  HoGG-LC  i.v.  I  I  I 
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FIo.  2.  D•se•responseandtime•c•urse•ft••eranceinducti•nusingi.v.injecti•n•fH•GG•m•dified 
lymphoid cells. "Bars represent mean ear swelling. 4-  SEM for groups of four mice. bMean A cpm 
in vitro response (X cpm 100 lag/culture HoGG--X cpm Nil) for quadruplicate 5-d cultures, c  Values 
in parentheses represent the percentages of suppression. * Significantly lower than positive controls 
P< 0.01. 
TABLE  III 




Day  In vivo response*  response:]: 
Exp.  Day -7  Day 0  4- 7 
group  tolerogen  sensitization  chal-  Ear  Toler-  vs.  vs. 
lenge  swelling  ance  HoGG  OVA 
× 10  -4 inch  %  A cpm  4- 8EM 
A  l0  s  HoGG-  250 lag HoGG-CFA i.t.  HoGG  11.5 4-  3.6  88.2§  140  -15 
LC i.v. 
B  --  250 lag HoGG-CFA i.t.  HoGG  62.1  ±  2.1  --  53,420  -210 
C  los  HoGG-  100 lag OVA-CFA i.t.  OVA  66.4  4-  2.5  -3.2  -  1,560  21,450 
LC i.v. 
D  --  100 lag OVA-CFA i.t.  OVA  64.5 4-  3.0  --  -2,490  20,300 
E  --  Saline-CFA i.t.  HoGG  4.7  4-  1.5 
OVA  4.7  4- 0.9  --  -1,430  330 
* Mean ear swelling response for groups of four to five mice 4- SEM. 
Mean A cpm in vitro response of draining LN cells vs. either 100 lag HoGG or 100 lag OVA per culture 
for quadruplicate 5-d cultures. 
§ Significantly less than positive controls P <  0.001. 
Specificity of Tolera,ce  Induction  by  Antigen-Modified  Lymphoid  Cells.  We  were  next 
concerned  with  the specificity of the tolerance  induced  by antigen-modified  LC.  To 
answer this question,  two  groups of mice were  tolerized on day  -7  with  10  s  HoGG- 
LC;  and  on  day  0,  one  group  was  sensitized  with  HoGG-CFA  and  the other  with 
OVA-CFA,  along with the appropriate  positive and  negative control groups. All mice 
were ear challenged with  10 #g of the appropriate  antigen on day 7, and increased ear 
swelling and  in vitro proliferation determined  24 h  later.  As can be seen in Table  III, 764  IMMUNITY AND TOLERANCE WITH ANTIGEN-MODIFIED  LYMPHOCYTES 
TABLE IV 
Specificity of Tolerance Induced by i.v. Injection of Gytochrome C Modified Syngeneic LC (Gyt C-LC) in 
SJL Mice 
In vivo response*  In vitro response:l:  Day 
Exp.  Day - 7  Day 0  + 7 
group  tolerogen  sensitization  chal-  Ear  Toler-  vs.  vs. 
Cyt  HoGG  lenge  swelling  ance  C 
× 10  -4 inch  %  A cpm  4- SEM 
A  l0  s Cyt C-LC  100 #g Cyt C-CFA i.t.  Cyt C  6.4 4-  1.1  94.8§  4,600  250 
i.V. 
B  --  100 ~g Cyt C-CFA i.t.  Cyt C  30.2 4-  1.8  --  15,610  -1,140 
C  10  s Cyt C-LC  250/zg  HoGG-CFA i.t.  HoGG  36.5 ±  2.9  8.7  -280  131,870 
i.v. 
D  --  250 #g HoGG-CFA i.t.  HoGG  39.5 ±  5.7  --  560  103,740 
E  --  Saline-CFA  i.t.  Cyt C  4.7 ±  1.5  -- 
HoGG  4.7 ±  0.9  --  50  -290 
* Mean ear swelling response for groups of four to five mice 4- SEM. 
:~ Mean A cpm in vitro response of draining LN cells vs. either 100 #g Cyt 
for quadruplicate 5-d cultures. 
§ Significantly less than positive controls P < 0.001. 
C or 100 #g HoGG per culture 
mice tolerized with HoGG-LG and sensitized with HoGG-CFA (group A) were nearly 
completely tolerant  as measured  by ear swelling or in  vitro cell  proliferation  when 
compared to positive controls (group B). However, similarly treated mice which were 
sensitized with OVA-CFA (group C) reacted the same as the OVA-positive controls 
(group D). Thus, the tolerant state induced by i.v. injection of HoGG-LC appears to 
be antigen-specific. 
Table IV illustrates  two additional points in this regard. The experimental  design 
is similar to the previous experiment,  except that SJL mice were tolerized with horse 
Cyt  C-modified  LC,  and  sensitized  with  either  Cyt  C-CFA or HoGG-CFA.  Again 
tolerance was specific as measured both in vivo or in vitro. Mice were unresponsive to 
Cyt C, but responded normally to HoGG. This experiment shows that SJL mice are 
appropriate for these studies and that the response to a very different protein  (Cyt C) 
can be suppressed by i.v. injection of antigen-coupled lymphoid cells. 
Dose-Response  and  Time-Course  of  Tolerance  Induction  with  Antigen-Modified  Lymphoid 
Cells.  We next  asked about  the optimal  quantities  of HoGG-LC needed  to induce 
tolerance  and  how  long  before  sensitization  do  they  need  to  be  given?  Groups  of 
BALB/e  mice  were  injected  i.v.  with  107,  5  ×  107, or  108  HoGG-LC  7  d  before 
sensitization,  and with  10  a HoGG-LC on day 4  and day  1 before sensitization  with 
250 #g HoGG-CFA i.t. The results are shown in Fig. 2 and illustrate two points. First, 
the  injection  of 10  a HoGG-LC at  7,  4, or  1 d  before sensitization  leads  to levels of 
tolerance which are approximately the same  (groups D-F).  This result  suggests that 
induction  of unresponsiveness  occurs very rapidly  in  that  mice tolerized  1 d  before 
sensitization respond as poorly as mice tolerized 4 or 7 d before sensitization. Second, 
increasing the amount of antigen-modified LC given 7 d  before sensitization leads to 
increased  levels of unresponsiveness  suggesting that  its  induction  is  dose-dependent 
(compare groups B-D).  The in  vitro response of mice given  108 HoGG-LC at  days S.  D.  MILLER,  R.  P  WETZIG,  AND  H.  N.  CLAMAN 
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In vivo response~ 
Group  Tolerogen  Cells transferred  Day 0  In 
-day*  on day 0  sensitization  Ear  Toler-  vitro§ 
swelling  ance 
× 10  -4 inch  %  A cpm  + SEM 
A  10  s  HoGG-LC  None--tolerance control  3  ×  10  v HoGG-  10.7  +  0.6[[  76.5  -2,010 
day -7  LC s.c. 
B  l0  s  HoGG-LC  8  X  107 LN +  8  X  107  3  X  107  HoGG-  18.7 +  1.6[[  55.9  8,220 
day -7  SP from group A  LC s.c. 
C  108  HoGG-LC  None--tolerance control  3  ×  107  HoGG-  11.8  ±  2.811  73.7  -2,820 
day -4  I..C s.c. 
D  l0  s  HoGG-LC  8  X  107 LN +  8  ×  107  3  X  107  HoGG-  22.2 ±  1.811  46.9  6,300 
day -4  SP from group C  LC s.c. 
E  l0  s  HoGG-LC  None--tolerance control  3  ×  107  HoGG-  8.6  ±  1.51[  82.0  -2,310 
day -  1  LC s.c. 
F  10  s  HoGG-LC  8  ×  107 LN +  8  ×  107  3  X  107  HoGG-  38.0  ±  1.3  6.2  7,660 
day -1  SP from group E  LC s.c. 
G  --  None--positive control  3  ×  107  HoGG-  40.4  :[: 3.6  --  7,430 
LC s.c. 
H  --  None--negative control  3  X  107  Sham-  1.6 3= 0.6  --  --830 
LC s.c. 
* BALB/c mice were tolerized with 10  s HoGG-LC on days -7, -4, and -1. On day 0, half of each group 
was sensitized with 3 ×  107 HoGG-LC s.c. and served as tolerant controls.  The other half of each group 
served as donors  of tolerant LN and spleen cells which were transferred to normal recipients who were 
sensitized with 3  ×  107 HoGG-LC within 1 h of cell transfer. 
:~ Values represent  mean ear swelling responses for groups of four mice ±  SEM. 
§ Mean A cpm (X 100 #g/culture HoGG -  X cpm Nil) for quadruplicate 5-d cultures. 
H  Values significantly lower than positive controls P <  0.01. 
-4  or -1  is completely suppressed  (groups  E  and  F)  while mice receiving the same 
dose of HoGG-LC  at  -7  d  shows  a  small degree of in  vitro proliferation  (group  D). 
Unresponsiveness  Induced by Antigen-Modified  Lymphoid  Cells  is  Transferable  by Antigen- 
Specific  Suppressor  T  Cells.  We next  asked  if the unresponsive  state  induced  by prior 
i.v. injection of HoGG-LC  was  transferable  to  normal  recipients  (Table V).  Groups 
of eight  BALB/c  mice  were  injected  with  10  a  HoGG-LC  i.v.  7,  4,  or  1  d  before 
transfer.  On  day 0, four of the mice in each group were sensitized by s.c.  injection of 
3  X  107  HoGG-LC  in  the  back;  these served  as  donor  tolerant  controls.  The  other 
four mice  in  each  group  were sacrificed  and  8  X  107  spleen  plus  8  ×  107  LN  cells 
transferred  to normal  recipients, which  were also sensitized with 3  ×  107  HoGG-LC 
s.c.  Positive controls  received the  same  number  of normal  cells before sensitization. 
Negative controls were sensitized with 3  ×  10  /sham-modified  LC. The results shown 
in Table V  indicate that  mice given HoGG-LC  from  1 to  7 d  before sensitization are 
very unresponsive  as  measured  by  in  vivo ear  swelling or  in  vitro  antigen-induced 
proliferation  (groups A, C, and E).  In contrast,  1 d  after tolerization with HoGG-LC, 
mice  although  fully  tolerant  exhibited  no  demonstrable  suppressor  cells  (group  F). 
However,  4  to  7  d  after  HoGG-LC  injection,  mice  were  both  fully  tolerant  and 
contained cells capable of transferring  unresponsiveness  to normal  recipients  (groups 
B  and  D).  These  results  suggest  that,  as  in  the DNFB  system  (5),  there  may  be two 766 
Cells  Transferred  a 
None- Donors  of 
Tolerant  LNC 
None - HoGG  Pas. Con. 
108  LNC 
10 8  LNC 
None-HoGG  Neg.Con. 
None-OVA  Pos.Con. 
10 8  LNC 
None-OVA Neg.Can. 
IMMUNITY AND TOLERANCE WITH ANTIGEN-MODIFIED  LYMPHOGYTES 
Ear  Swelling  (xl0 -4  inch)  ."  SEM b 
Treatment  of  0  10  20  30  40  50  60  70 
Tolerant  Cells  I  I  I  I  I  I  I 
NRS  • C' 
Anti-e  ÷ C' 
I  (88.2)d  -X  - 
,,°.3,. 
+ 
I~  (5.9)  NS 
In  Vitro  A  cpm c 
vs. HoGG  vs. OVA 
140  -15 
53420  -210 
7Z370  -520 
63080  300 
-1430 
2490  20300 
-1430  I~290 
330 
B 
N,s.c  (2 
P  ~ 
:HoGG  Sensitized 
zOVA  Sensitized 
Ftc.  3.  Cellular nature  and antigen-specificity of suppressor cells induced by i.v. injection of 
HoGG-modified lymphoid cells. "Donor mice were tolerized 7 d before transfer by i.v. injection of 
S  b  ....  10  HoGG-LC. Bars  represent mean ear swell,ng response + SEM for groups of four mice sons,treed 
and challenged with either HoGG (open bars--upper panel) or OVA (hatched bars--lower panel). 
CMean A cpm in vitro response of draining LN cells vs. either  100 #g/culture  HoGG or 100 #g/ 
culture OVA for quadruplicate  5-d cultures, aValues in parentheses represent the percentages of 
suppression. "Significantly lower than positive controls P < 0.01. NS, no significant difference. 
distinct  mechanisms of tolerance operating in this system. The first is an immediate 
blockade of reactive T-cell clones, and the second is a period of suppressor cell activity 
which takes 4-7 d  to develop.  The in vitro proliferation  data  also indicate  that  the 
transferred suppressor cells were not capable of blocking the in vitro proliferation  of 
T  cells in the recipients, although the recipients' ear swelling responses were dramat- 
ically decreased. 
The cellular nature and specificity of the suppressor cells in this system were next 
examined  (Fig. 3).  BALB/c mice were tolerized on day -7  with  10  s HoGG-LC. On 
day 0,  LN cells  were  removed,  treated  with  NRS  +  C' or with  anti-0  +  C',  and 
transferred  into normal recipients.  The recipients were sensitized with either HoGG- 
CFA or OVA-CFA, along with the appropriate control groups. 7 d after sensitization, 
mice were ear challenged and ear swelling and in vitro proliferation  measured  24 h 
later.  Group A  shows that the donors of the tolerant  LN cells were 88% tolerant  and 
their  cells  failed  to respond  in  vitro.  Recipients  of NRS  +  C'-treated  tolerant  LN 
cells  (group C)  were 46%  suppressed,  but  recipients  of anti-0  +  C'-treated  tolerant 
LN cells  (group D)  were only 6% suppressed.  Thus, the suppression  requires  cells of 
the T-cell lineage. The antigen-specificity of the T8 is shown by the fact that recipients 
ofNRS  +  C'-treated tolerant LN cells who were sensitized and challenged with OVA 
responded  normally  both  by ear  swelling  and  in  vitro  proliferation  (group  G).  It 
should be noted that cells of the suppressed recipients of tolerant  LN cells (group C) 
again responded normally in the proliferation assay. 
Discussion 
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in mice and has described the induction of tolerance in this system. A CMI response 
to HoGG, OVA, or Cyt C  could be induced by two methods:  injection of protein 
emulsified in CFA into the base of the tail or by the s.c. injection into the dorsal skin 
of protein-coupled syngeneic lymphoid cells. After these methods of sensitization, ear 
challenge with the appropriate free antigen was followed by ear swelling which was 
significant at 24 but not at 4 h, typical of a delayed hypersensitivity response. The T- 
cell dependence of the response is illustrated by the fact that transfer of sensitivity is 
accomplished by 0-sensitive lymphoid cells, and not by serum. After these sensitization 
regimens, mice have T  cells in the regional nodes which proliferate in vitro when 
challenged with the appropriate antigen (17). 
The  use  of cell-coupled  haptens  for  the  induction  of T-cell-mediated  contact 
sensitivity reactions  has  been  described  both  for  guinea  pig  and  mouse  models. 
Baumgarten and Geczy (10) and Polak and Macher (11) showed that DNP-modified 
lymphocytes injected either i.p. or intradermally in guinea pigs could induce DNP- 
specific contact sensitivity. More recently, Green et al. and Bach et al. applied this 
methodology to a mouse model and showed that s.c. injection of TNP- or azobenzene- 
arsonate (ABA)-modified lymphoeytes lead to the development of significant delayed 
hypersensitivity responses  (12,  13). The present study extends this methodology to 
induction of CMI responses to soluble protein antigens coupled to syngeneic lympho- 
cytes. This induction of CMI responses by s.c. injection of antigen-modified lymphoid 
cells provides a powerful tool for the study of induction of, genetic constraints on, and 
mechanisms of, antigen-specific T cells without concern for nonspecific effects of CFA. 
To produce tolerance to the CMI induced with protein antigens, the same prepa- 
rations of protein-modified LC were merely injected  i.v.  before sensitization. The 
tolerance produced was (a) rapid, (b) specific, and (c) more efficient (in terms of dose 
of tolerogen)  than that  induced by i.v.  injection of free protein.  Furthermore,  i.v. 
tolerogens also led to the production of antigen-specific T  suppressors  Ors) able to 
transfer suppression to naive recipients. Finally, analysis of the kinetics of the induction 
of tolerance and of suppression leads us to conclude that in this system, as in tolerance 
to DNP-LC, two mechanisms of unresponsiveness exist:  a  rapidly-induced state of 
clone inhibition (not associated with Ts) and the later development of T~.  1 d  after 
tolerization  with  i.v.  protein-LC,  mice  were  unresponsive  but  could  not  transfer 
unresponsiveness to normal recipients (i.e. had no demonstrable T~). 4 and 7 d after 
tolerogen, mice were unresponsive and also contained T~. This dichotomy between 
unresponsiveness due to clone inhibition and that due to T~ is also seen in tolerance 
to  antibody formation induced by  deaggregated  y-globulins  (20-22)  where  active 
suppression is present only briefly, while the tolerant cells remain unresponsive for a 
much longer period of time. 
An  interesting feature of the T~ induced by injection of HoGG-LC is  that  they 
suppress the TDH cells responsible for mediating the ear swelling response, but fail to 
suppress  the development of the T  cell which proliferates in  vitro upon  antigenic 
restimulation. We propose two possible explanations for this phenomenon. First, it is 
possible  that  T~ act  by suppressing  the efferent  (or elicitation)  phase  of the CMI 
response (23). They therefore may not block the development of the in vitro prolif- 
erative cells which seems to be a process which occurs during the afferent (sensitization) 
phase. A second possible explanation is that the T8 may act only on the TDH cell, but 
not on the in vitro proliferating T  cell. It is now clear that  in the DNFB contact 
sensitivity system TDH and proliferating T  cells belong to separate T-cell lineages. 768  IMMUNITY AND TOLERANCE WITH ANTIGEN-MODIFIED LYMPHOCYTES 
Moorhead  (24) has shown that TDH cells in that system are nonadherent to nylon 
wool and are Ia-, while the in vitro proliferating T  cell is adherent and Ia  +. These 
findings agree with those of Vadas et al.  (25)  who showed that in CMI to fowl y- 
globulin, the cells responsible for the in vivo transfer of CMI were also Ia-. Experi- 
ments to distinguish between these two possibilities and at what level T, mediate in 
vivo suppression (i.e. induction or expression) are currently being performed. 
Mode of Antigen Presentation in T-Cell Function.  In analyzing these results, we think 
in terms of three events and two types of antigen-specific T  cells.  These are:  (a) the 
development of CMI via stimulation of TDH, (b) rapid induction of tolerance via clone 
inhibition  of these  TDH, and  (c)  slower  development  of infectious  tolerance  via 
stimulation ofT,. Thus there are two net results for the TDn--a turn-on (sensitization) 
or a turn-off (clone inhibition unresponsiveness). In the context of this paper, there is 
only one result of triggering precursors of 'Is which is to cause the development of 
active T,.  (Such cells can be non-specifically eliminated, e.g. by cyclophosphamide 
[5], but we are not aware of specific turn-off signals for T,.) 
As a  result of an enormous amount of recent research, it is now clear that T  cells 
recognize antigens in association with MHC products (26, 27). Recent studies on the 
development of contact sensitivity responses in vivo (12) and the induction of T-cell 
proliferation  in  vitro  (28) have  also  suggested  an  important  role  for macrophage 
presentation. 
Thus, effective immunogenicity seems to involve macrophage-associated antigenic 
determinants presented to the appropriate T cell in conjunction with MHC products. 
The elegant  transfer experiments  of Vadas  et  al.  (27)  in  CMI  to  fowl y-globulin 
suggested that T cells mediating DTH responses recognize antigen in association with 
Ia region determinants. It is likely that the antigen-presenting cell in contact sensitivity 
is an Ia  + maerophage-like Langerhans cell in the skin (29) which thus conjugates with 
topically applied DNFB. We believe that this is what is recognized by the TDn and 
what activates it during contact sensitization. 
It is difficult to induce CMI to proteins in mice without adjuvants such as CFA. 
While the action(s) of adjuvants are still not fully understood, it is likely that the 
intense inflammation may facilitate interaction of macrophages with the suspended 
protein,  thus  favoring immunogenic  presentation  to  T  cells.  In  the  experiments 
described here, we found that proteins were immunogenic in CFA but also equally 
immunogenic if bound to lymphoid cells and given subcutaneously without CFA. We 
believe that the effectiveness of this regimen depends on the fact that subcutaneous 
cell-bound antigen is particularly efficient in becoming associated with MHC products 
of macrophages which are in, or which reach, the regional lymph nodes.  It is this 
macrophage-antigen-major  histocompatibility  complex  (MHC)  product  complex 
which is seen by the T  cells in the lymph node and which activates them. 
In terms of turning off TDrt in the rapid development of unresponsiveness (which 
we call clone inhibition), it is also clear that the most effective tolerogens are those 
bound to cells.  In contact sensitivity to DNFB, chemicals which don't couple cova- 
lently  to  self are  not  tolerogenic  (1).  Furthermore,  DNP  coupled  to  proteins  or 
polypeptides may be good tolerogens for B cells (30, 31), but these soluble antigens do 
not  produce  rapid  clone  inhibition  in  contact  sensitivity  (4,  32).  There  is  some 
information that  the MHC  must  be  involved in  this clone inhibition since DNP- 
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inhibition (4). Thus, again, it is not surprising that protein coupled to nucleated cells 
containing MHC products can, when presented by the proper route  (i.v.  not s.c.), 
induce clone inhibition.  This clone inhibition probably occurs after the arrival of 
blood-borne cell-bound protein in the lymph nodes, as these are the site of immuni- 
zation by cell-bound protein given s.c. To prevent this immunization, we believe that 
the i.v.  cell-bound protein  is delivered to the lymph nodes in a  way which allows 
direct presentation to the antigen receptors on Toil. Frei et al. put forward the concept 
that  immunogenicity  involves  macrophage  processing  of antigen,  and  tolerance 
involves bypassing the macrophages with direct presentation of antigen to lympho- 
cytes (33).  As we presently believe that T  cells see antigens best  in the context of 
membrane presentation, this concept is quite compatible with the data showing the 
tolerogenicity of cell-bound antigens. In this case, therefore, the turn-off signal to the 
TDn would involve presentation of antigen on a  cell membrane, but via a  nonim- 
munogenic (perhaps  a  nonmacrophage)  pathway. Although we do not know what 
this nonimmunogenic pathway may be, it could involve presentation via nonmacro- 
phage membranes in a situation where the ordinary positive triggering signal is not 
delivered to the TDH. 
It should also be noted that HoGG associated with LN without ECDI is a  potent 
tolerogen  (Table  II--group  1B). Presumably,  the  HoGG  is  bound  to  LC  via  Fc 
receptors. The tolerogenicity of such a cell-protein complex suggests that cell-bound 
molecules do not have to be covalently linked to the cell membrane. 
The third event in these experiments, i.e. the development of T,, also requires the 
presentation  of cell-bound  antigen.  This  appears  to  be  true  because,  using  the 
arguments in the previous paragraph, materials which are not cell-associated not only 
fail to produce clone inhibition but also do not produce Ts. We have previously shown 
in suppression of DNFB contact sensitivity (34) that compatibility at the H-2D region 
of the MHC between the DNP-modified lymphoid membrane tolerogen and the T, 
donor mouse is both sufficient and necessary for T8 induction. Thus, it would appear 
that in that system the T8 precursors are triggered by hapten-modified H-2D region 
determinants.  Whether  this  relationship  is  operating  in  T,  induction  by  protein 
antigen-modified lymphoid cells is currently under investigation. Recent work in our 
laboratory  has  also  suggested  that  I  region  compatibility  between  the  DNP-LC 
tolerogen and tolerized mice is necessary for the induction of rapid clone inhibition 
(i.e. tolerance induced within 1 d). This would explain the fact that i.v. injection of 
DNP-RBC (lacking I region determinants), as opposed to DNP-LC, does not lead to 
rapid tolerance induction (4), but does eventually lead to T, induction (3). 
Again, however, the production of T, by cell-bound antigen also depends greatly 
on the mode of presentation. Cell-bound protein given i.v. leads to the production of 
"Is. We have previously shown that the spleen is required for at least some forms of T8 
activation (35). As many i.v. protein-modified LC will travel to the spleen, we think 
it  likely that  this blood-borne  presentation  will stimulate the production  of T8 or 
suppressive factors which can leave the spleen to suppress Ton in lymph nodes. We 
do not know whether splenic macrophages are important in this process, but it has 
been suggested by Feldmann and Kontiainen (36) and by Benacerraf and Germain 
(37) that bypass of macrophage processing may be an important step in triggering of 
Ta. 
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mediated immunity and tolerance (plus suppression)  to protein antigens in a mouse 
model. T~ can be induced with relatively low doses of membrane-bound antigen, as 
opposed to other systems where high doses of deaggregated globulins (38) are required 
for  T~  induction.  The  use  of membrane-bound  antigens  as  tolerogens  may also 
circumvent problems recently described by Parks et al. (39) in the human y-globulin 
system where different preparations of deaggregated material induced very variable 
Ts activities  (in some cases no demonstrable T~). The use of membrane-associated 
protein antigens may also allow the induction of tolerance in systems where soluble 
proteins are not effective tolerogens. In this regard, W  e have obtained recent evidence 
(S.  D.  Miller and J.  M. Chiller, unpublished observations)  that human y-globulin 
coupled LC are effective tolerogens for both CMI and antibody production in BALB/ 
c mice, which are historically difficult to tolerize even with high doses of deaggregated 
y-globulins (40, 41). It is hoped that eventually the use of antigen-modified autologous 
lymphoid cells as  tolerogens  can  be  used  clinically to  modulate harmful T-cell- 
mediated immune responses such as autoimmune states. 
Summary 
A mouse model of  cell-mediated immunity (CMI) and tolerance to protein antigens 
horse gamma globulin (HoGG)  and eytochrome (Cyt C) was invesigated. A reliable 
CMI response as measured in vivo by ear swelling or by an in vitro T-cell proliferation 
assay could be induced by one of two methods: (a) sensitization by antigen-complete 
Freund's adjuvant in the base of the tail, or (b) sensitization by s.c. injection of antigen 
coupled to syngeneic lymphoid cells. The in vivo response  exhibited characteristic 
CMI parameters, delayed kinetics, and transfer by viable T cells. 
Prior i.v. injection of HoGG-modified lymphoid cells  (HoGG-LC) or Cyt C-LC 
before  sensitization resulted in a  rapidly induced, dose-dependent, antigen-specific 
suppression  of both  in  vivo  and  in  vitro  manifestations of the CMI  response.  In 
addition, tolerance in this system was transferrable by an antigen-specific suppressor 
T  cell  (Ts). The Ts were  found to  diminish the  in  vivo  ear  swelling  reaction  in 
recipient  animals, but had no effect on the in vitro T-cell proliferative response of the 
recipients. In contrast to the rapid development of  tolerance in donor mice (phenotypic 
tolerance),  transferrable T~ were first demonstrable 4-7 d posttolerization. This latter 
result indicates that at least two mechanisms of tolerance are operative in this system: 
the rapid induction of clone inhibition of reactive T cells and the slower induction of 
Ts. 
These results  indicate again that the mode of antigen presentation is crucial in 
determining the  immunologic outcome. In  these experiments, cell-bound proteins 
injected  subcutaneously led  to  delayed hypersensitivity while  the  same  antigens 
injected intravenously led to tolerance. 
These results are considered in the light of recent experiments which show that T 
cells recognize antigens on cells in association with major histocompatibility complex 
products.  We  believe  the  following  pathways  are  involved.  In  sensitization  via 
subcutaneous injection of HoGG-LC, antigen reaches the lymph node via lymphatic 
pathways which lead to immunogenic macrophage-associated presentation and the 
activation of delayed hypersensitivity T  cells (TDn). In tolerization via intravenous 
injection of HoGG-LC, antigen (a)  reaches  the lymph node via the blood, probably 
directly meeting the  TDH, preventing  its  subsequent  activation by  immunogenic S.  D.  MILLER, R.  P WETZIG,  AND  H.  N.  CLAMAN  771 
HoGG  (clone  inhibition)  and  (b)  reaches  the  spleen,  also  via the  blood,  activating 
suppressor T  cells. 
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